177 related articles for article (PubMed ID: 27627882)
1. ReRouting biomedical innovation: observations from a mapping of the alternative research and development (R&D) landscape.
Greenberg A; Kiddell-Monroe R
Global Health; 2016 Sep; 12(1):54. PubMed ID: 27627882
[TBL] [Abstract][Full Text] [Related]
2. Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil.
Kameda K
Dev World Bioeth; 2014 Aug; 14(2):101-8. PubMed ID: 24761744
[TBL] [Abstract][Full Text] [Related]
3. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.
Germann PG; Schuhmacher A; Harrison J; Law R; Haug K; Wong G
Hum Genomics; 2013 Mar; 7(1):5. PubMed ID: 23496921
[TBL] [Abstract][Full Text] [Related]
4. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
5. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
Simpkin VL; Renwick MJ; Kelly R; Mossialos E
J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Open innovation in early drug discovery: roadmaps and roadblocks.
Reichman M; Simpson PB
Drug Discov Today; 2016 May; 21(5):779-88. PubMed ID: 26743597
[TBL] [Abstract][Full Text] [Related]
8. Repairing the broken market for antibiotic innovation.
Outterson K; Powers JH; Daniel GW; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
[TBL] [Abstract][Full Text] [Related]
9. The Health Impact Fund: a potential solution to inequity in global drug access.
Banerjee A; Pogge T
Indian J Med Ethics; 2010; 7(4):240-3. PubMed ID: 22106579
[TBL] [Abstract][Full Text] [Related]
10. Poverty, health & intellectual property rights with special reference to India.
Satyanarayana K; Srivastava S
Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
[TBL] [Abstract][Full Text] [Related]
11. [Alternatives to the drug research and development model].
Velásquez G
Salud Colect; 2015 Mar; 11(1):23-34. PubMed ID: 25853828
[TBL] [Abstract][Full Text] [Related]
12. [What is the fair price of innovative therapy?].
Fischer A; Dewatripont M; Goldman M
Med Sci (Paris); 2020 Apr; 36(4):389-393. PubMed ID: 32356716
[TBL] [Abstract][Full Text] [Related]
13. Can open-source drug R&D repower pharmaceutical innovation?
Munos B
Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
[TBL] [Abstract][Full Text] [Related]
14. How Indian biotech is driving innovation.
Nogrady B
Nature; 2018 Dec; 564(7735):S53-S55. PubMed ID: 30542184
[No Abstract] [Full Text] [Related]
15. Leveraging Industry-Academia Collaborations in Adaptive Biomedical Innovation.
Stewart SR; Barone PW; Bellisario A; Cooney CL; Sharp PA; Sinskey AJ; Natesan S; Springs SL
Clin Pharmacol Ther; 2016 Dec; 100(6):647-653. PubMed ID: 27617845
[TBL] [Abstract][Full Text] [Related]
16. Obstacles and opportunities in Chinese pharmaceutical innovation.
Ni J; Zhao J; Ung CO; Hu Y; Hu H; Wang Y
Global Health; 2017 Mar; 13(1):21. PubMed ID: 28340579
[TBL] [Abstract][Full Text] [Related]
17. Developing the latest framework to measure and incentivise pharmaceutical industry contributions to health research and development.
Cole CB; Trolle S; Edwards DJ
Health Res Policy Syst; 2018 Aug; 16(1):73. PubMed ID: 30071858
[TBL] [Abstract][Full Text] [Related]
18. New strategies for innovation in global health: a pharmaceutical industry perspective.
Witty A
Health Aff (Millwood); 2011 Jan; 30(1):118-26. PubMed ID: 21209447
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
